PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants

Completed · Phase 1

Conditions studied: Healthy Participants

In brief

This is a drug-drug interaction study to assess the effects of PF-07321332/ritonavir and ritonavir on the Pharmacokinetic (PK) of dabigatran in healthy volunteers. PK will be evaluated for PF-07321332 and ritonavir. Dabigatran is being utilized as a P-gp substrate

Key facts

Study ID

NCT05064800

Run by

Pfizer

People needed

24

Starts

2021-09-21

Expected to finish

2021-12-06

Last updated by the study team

2024-03-29

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Body Mass Index (BMI) of 17.5 to 30.5 kg.m2; and a total body weight >50 kg (110 lbs)
• Female participants must have a negative pregnancy test

You may not qualify if…

• Positive test for SARS-Co-V2 at the time of screening or Day -1
• Active pathological bleeding or risk of bleeding
• Positive urine drug test
• History of sensitivity to heparin or heparin induced thrombocytopenia
• Participants who have been vaccinated for COVID-19 in the past 7 days

Where it is running

• Research Centers of America ( Hollywood ) — Hollywood, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.